Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–178 of 178 matching trials from the live ClinicalTrials.gov search.
Conditions
Liquid Oxycodone
Interventions
liquid oxycodone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 8 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Accepts healthy volunteers

Cannabis Versus Oxycodone for Pain Relief

NCT02892591
Conditions
Back Pain, Neck Pain
Interventions
Cannabis, Oxycodone, Placebo for Cannabis, Placebo for Oxycodone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Not yet recruiting Phase 4 Interventional

Post-op Analgesia of Nail Unit Procedures

NCT07820969
Conditions
Nail Diseases
Interventions
Suzetrigine, Oxycodone/Acetaminophen, Acetaminophen, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Anterior Cruciate Ligament Injury, ACL Injury, ACL - Anterior Cruciate Ligament Rupture
Interventions
Femoral Nerve Block, Adductor Nerve Block, No Block
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Locally Advanced Head and Neck Cancer
Interventions
Xtampza ER
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Opioid Use, Substance Use Disorders, Opioid Analgesia
Interventions
Placebo, Oxycodone HCl, Kratom 8g, Kratom 12g, Kratom 16g, Kratom 4g
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pharmacokinetics, Healthy Volunteer
Interventions
PF614 capsule, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Not listed Phase 4 Interventional Accepts healthy volunteers

Pain Control After Lumbar Spine Fusion

NCT06484192
Conditions
Spine Fusion, NSAID (Non-Steroidal Anti-Inflammatory Drug), Postoperative Pain
Interventions
Naproxen 500 Mg, Ketorolac, OxyCODONE 5 mg Oral Tablet, Metaxalone 800 MG
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prescription Opioid Effects in Abusers Versus Non-Abusers

NCT00158184
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
oxycodone 15 mg, oxycodone 30 mg, Placebo 0 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more